Birchview Capital’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q2 | – | Sell |
-372,557
| Closed | -$387K | – | 58 |
|
|
2019
Q1 | $387K | Buy |
372,557
+200,000
| +116% | +$163K | 0.24% | 36 |
|
|
2018
Q4 | $129K | Buy |
172,557
+53,868
| +45% | +$81.1K | 0.12% | 45 |
|
|
2018
Q3 | $252K | Buy |
118,689
+20,000
| +20% | +$47.9K | 0.16% | 46 |
|
|
2018
Q2 | $228K | Hold |
98,689
| – | – | 0.16% | 41 |
|
|
2018
Q1 | $314K | Buy |
98,689
+70,000
| +244% | +$193K | 0.21% | 36 |
|
|
2017
Q4 | $118K | Hold |
28,689
| – | – | 0.07% | 39 |
|
|
2017
Q3 | $130K | Hold |
28,689
| – | – | 0.07% | 39 |
|
|
2017
Q2 | $96K | Sell |
28,689
-6,000
| -17% | -$24.9K | 0.05% | 39 |
|
|
2017
Q1 | $319K | Sell |
34,689
-36,000
| -51% | -$316K | 0.18% | 27 |
|
|
2016
Q4 | $545K | Hold |
70,689
| – | – | 0.34% | 18 |
|
|
2016
Q3 | $808K | Hold |
70,689
| – | – | 0.47% | 15 |
|
|
2016
Q2 | $870K | Hold |
70,689
| – | – | 0.63% | 13 |
|
|
2016
Q1 | $715K | Buy |
70,689
+12,000
| +20% | +$141K | 0.51% | 15 |
|
|
2015
Q4 | $1.32M | Hold |
58,689
| – | – | 0.76% | 10 |
|
|
2015
Q3 | $974K | Hold |
58,689
| – | – | 0.63% | 14 |
|
|
2015
Q2 | $1.32M | Buy |
58,689
+14,000
| +31% | +$345K | 0.7% | 15 |
|
|
2015
Q1 | $1.15M | Buy |
44,689
+22,200
| +99% | +$563K | 0.61% | 14 |
|
|
2014
Q4 | $489K | Buy |
+22,489
| New | +$461K | 0.28% | 24 |
|
Birchview Capital's OMED Position: Q2 2019 in Review
Birchview Capital sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q2 2019, closing a stake of 372,557 shares — an estimated $387K sold.
Birchview Capital first reported a position in OMED in Q4 2014 and held it in 18 quarters. The position peaked at $1.32M in Q4 2015. 0 funds tracked by Wall St. Rank hold OMED as of Q2 2019.
- Birchview Capital reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
- Birchview Capital sold 372,557 OncoMed Pharmaceuticals, Inc. shares in Q2 2019, an estimated $387K.
- Birchview Capital first reported a position in OncoMed Pharmaceuticals, Inc. in Q4 2014 and held it in 18 quarters.
- Birchview Capital's OncoMed Pharmaceuticals, Inc. position peaked at $1.32M in Q4 2015.
- 0 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q2 2019.
Based on Birchview Capital's 13F filing for Q2 2019, filed 6 Aug 2019.